Cyclopentenone: a special moiety for anticancer drug design.
The conjugate cyclopent-en-one chemical group is a special moiety for anticancer drugs. Studies on cyclopentenone prostaglandins, clavulones and other compounds have revealed its mechanism of action and a wide spectrum of intracellular targets, ranging from nuclear factors to mitochondria. The introduction of the cyclopentenone moiety into molecules, such as jasmonates and chalcones, has been shown to boost their anticancer potential. In this work, reviewing pertinent up-to-date literature, we have pointed out potentially effective cyclopentenone-bearing compounds for anticancer clinical research and inspiring relationships for future drug design. In particular, it appears that the addition of cyclopentenone groups to target-orienting molecules, in order to inactivate specific proteins in cells, could be a helpful general strategy for the development of novel therapeutic molecules.
Conti
Matteo
M
Laboratory of Clinical Pharmacology and Toxicology, IRST-IOR Oncology Research Institute, S. Maria delle Croci Hospital, Ravenna, Italy. matteoconti@alice.it
D000818:Animals; D000970:Antineoplastic Agents / Q000494:pharmacology*; D003517:Cyclopentanes / Q000494:pharmacology*; D015195:Drug Design; D006801:Humans; D011453:Prostaglandins / Q000494:pharmacology; D011454:Prostaglandins A / Q000494:pharmacology; D013329:Structure-Activity Relationship
D000970:Antineoplastic Agents; D003517:Cyclopentanes; D011453:Prostaglandins; D011454:Prostaglandins A; C046249:clavulones; C013905:cyclopentenone